Ixazomib for Multiple Myeloma
This study is evaluating whether a new drug called ixazomib is more effective than bortezomib.
See full descriptionAbout the trial for Multiple Myeloma
Treatment Groups
This trial involves 2 different treatments. Ixazomib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Ixazomib will improve 1 primary outcome and 1 secondary outcome in patients with Multiple Myeloma. Measurement will happen over the course of Assessed at baseline and end of study, up to 2 years, end of study reported.
Patient Q & A Section
Can multiple myeloma be cured?
The response rate to bortezomib of 50% or more was found to be a good indicator for prolonged remission at one year. This rate is comparable to many previously published results of the European Commission-approved dose schedules. Bortezomib should be considered as a therapeutic option in patients with multiple myeloma, even in the most critical settings as long as treatment results are carefully monitored.
What are common treatments for multiple myeloma?
The most common treatments for multiple myeloma are proteasome inhibitor treatment plus dexamethasone for induction, thalidomide, and bortezomib for consolidation, and autologous stem cell transplantation . In addition, if you want to join a new clinical trial, you can search recent trials by treatment, condition, or location.
What are the signs of multiple myeloma?
Hypercalcaemia, anorexia and abdominal pain are common. Increased kidney function can occur early on and can indicate the presence, and later stage, of multiple myeloma. The degree of renal impairment can predict the time of death.\n
What is multiple myeloma?
Multiple myeloma affects males more often than females. In our area, nearly all patients are over the age of 70 before diagnosis and patients diagnosed before age 40 have a survival comparable with patients diagnosed later. Survival from multiple myeloma remains short and depends on the disease-free interval, number of courses of therapy, age, and comorbidities at diagnosis.
What causes multiple myeloma?
The causes of multiple myeloma are complex, and vary between the American and European populations. The association between multiple myeloma and infection appears to differ between American and European populations. In the U.S. we have found a clear association while in Europe the data are not as clear-cut.
How many people get multiple myeloma a year in the United States?
The National MM Registry of the US National Cancer Institute (USNCI) estimates over 19,000 multiple myeloma patients will be diagnosed in the United States in 2020. The number who are currently diagnosed with multiple myeloma is approximately 10,000 (range 6,000 to 12,000). This number is expected to increase by 3,500 cases over the next 10 years.
What is the latest research for multiple myeloma?
There is a limited number of studies and studies are of varying quality. The majority of the trials were single center, of low quality and have results that cannot be generalized. There are no adequately powered prospective randomized controlled trials. Trials should include more patients, study larger geographical areas, and examine the effect of sequential therapies that are known to be effective in relapsed and refractory disease.
How quickly does multiple myeloma spread?
The median survival in the United States declined by 11% between 2003 and 2004, but more than half of these deaths occurred in people under 60. The percentage of people with multiple myeloma living 10 years or longer almost doubled between 2001 and 2003, which suggests that multiple myeloma is slowly gaining on-stage survivors.
How serious can multiple myeloma be?
Survival following treatment with ASCT is longer for all stages of myeloma, although mortality rates still exist. In particular, ASCT has prolonged life and may improve outcomes in patients with myeloma at stage 3 or 4 with ISS or in those older than 80 years with no ISS.
Is ixazomib typically used in combination with any other treatments?
Ixazomib is used as a single agent or in combination with a number of treatments in the treatment of multiple myeloma and in combination with a number of agents in other solid tumors, even in patients with CNS involvement and with bortezomib-refractory disease.
Who should consider clinical trials for multiple myeloma?
[A large fraction of patients are eligible for MMM with an acceptable complication rate and low treatment delay to follow-up visits. However, the vast majority of trials in MMM have poor power and are likely to reach type II error or even fail to achieve type I error because of inclusion criteria; therefore, patients should probably not be excluded unnecessarily unless there are other concerns.]{Read more about this decision-making process at http://www.withpower.
What is the primary cause of multiple myeloma?
Genetic predisposition, environmental factors or a combination of both may account for the onset of MM in individual patients. These factors differ from patient to patient indicating different pathogeneses.